Journals / Düzce Tıp Fakültesi Dergisi / 2021 / Cilt: 23 - Sayı: 2

Soluble ST2 in Predicting Adverse Outcome after Revascularization with Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction

ST-Yükselmeli Miyokard Enfarktüslü Hastalarda Perkütan Koroner Girişim ile Revaskülarizasyon Sonrası Advers Sonucu Öngörmede Çözünür ST2

Pages
174–180
Publication Date
2021-08-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: sST2 is highly associated with the degree of blood flow recovery after percutaneous coronary intervention in patients with STEMI and is of great clinical importance as a prognostic marker.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of the study was to investigate the relationship between the soluble suppression of tumorigenicity 2 (sST2) level and the degree of epicardial blood flow recovery in patients with myocardial infarction with ST-segment elevation (STEMI) after percutaneous coronary intervention.
📊
Key Findings & Data:Material and Methods: The study involved 61 patients (83.6% males), with a mean age of 59.85±10.01 years. sST2 level was measured by enzyme immunoassay.
💡
Conclusion & Impact:Conclusion: sST2 is highly associated with the degree of blood flow recovery after percutaneous coronary intervention in patients with STEMI and is of great clinical importance as a prognostic marker.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:akut miyokard infarktüsü · sST2 · “no-reflow” fenomeni

Abstract

Aim: The aim of the study was to investigate the relationship between the soluble suppression of tumorigenicity 2 (sST2) level and the degree of epicardial blood flow recovery in patients with myocardial infarction with ST-segment elevation (STEMI) after percutaneous coronary intervention. Material and Methods: The study involved 61 patients (83.6% males), with a mean age of 59.85±10.01 years. sST2 level was measured by enzyme immunoassay. Patients were divided into two groups. The first group (n=12) included patients with thrombolysis in myocardial infarction (TIMI) ≤II flow grade, the second group (n=49) with TIMI III flow grade. Results: The sST2 level was significantly higher in the first hours of the disease in the group with decreased epicardial blood flow (TIMI ≤II) after percutaneous coronary intervention (p=0.003). Receiver operating characteristics curve analysis showed that sST2 levels over 34.2 ng/ml, detected on admission, was an independent predictor of adverse revascularization (TIMI ≤II) in patients with STEMI with a sensitivity of 92.3% and a specificity of 62.5%; the area under curve was 0.811 (95% CI: 0.651 - 0.873; p=0.001). Both the univariate (OR: 1.020, 95% CI: 1.001-1.041, p=0.028) and multivariate (OR: 1.030; 95% CI: 1.002-1.057; p=0.033) analyzes showed that sST2 was a significant predictor of the unfavorable outcome of epicardial vascular revascularization (TIMI ≤ІІ). Conclusion: sST2 is highly associated with the degree of blood flow recovery after percutaneous coronary intervention in patients with STEMI and is of great clinical importance as a prognostic marker.

Özet

Amaç: Bu çalışmanın amacı, ST-segment yükselmesi (STEMI) olan miyokard enfarktüslü hastalarda perkütan koroner girişim sonrası tümörijenisitenin çözünür baskılanması 2 (soluble suppression of tumorigenicity 2, sST2) seviyesi ile epikardiyal kan akımının düzelme derecesi arasındaki ilişkinin araştırılmasıdır. Gereç ve Yöntemler: Çalışmaya ortalama yaşı 59.85±10.01 yıl olan 61 hasta (%83,6 erkek) dahil edildi. sST2 seviyesi enzim immunoassay ile ölçüldü. Hastalar iki gruba ayrıldı. Birinci grup (n=12) miyokard enfarktüsünde tromboliz (thrombolysis in myocardial infarction, TIMI) ≤II akım dereceli hastaları, ikinci grup (n=49) ise TIMI III akım dereceli hastaları içeriyordu. Bulgular: Epikardiyal kan akımı azalmış (TIMI≤II) olan grupta perkütan koroner girişim sonrası hastalığın ilk saatlerinde sST2 düzeyi anlamlı olarak daha yüksekti (p=0.003). Alıcı işlem karakteristiği eğrisi analizi, başvuru sırasında saptanan 34,2 ng/ml'nin üzerindeki sST2 düzeylerinin, STEMI hastalarında %92,3 duyarlılık ve %62,5 özgüllük ile advers revaskülarizasyonun (TIMI ≤II) bağımsız bir ön gördürücüsü olduğunu göstermiştir; eğri altında kalan alan 0,811 (%95 GA: 0,651 - 0,873; p=0,001) idi. Hem tek değişkenli (OR: 1,020; %95 GA: 1,001-1,041; p=0.028) ve hem de çok değişkenli (OR: 1,030; %95 GA: 1,002-1,057; p=0.033) analizler sST2'nin epikardiyal vasküler revaskülarizasyonun olumsuz sonucunun (TIMI≤ІІ) anlamlı bir ön gördürücüsü olduğunu gösterdi. Sonuç: sST2, STEMI olan hastalarda perkütan koroner girişim sonrası kan akımındaki iyileşme derecesi ile yüksek oranda ilişkilidir ve prognostik bir belirteç olarak büyük klinik öneme sahiptir.

🔖

Cite This Article

KOPYTSYA, M., HİLOVA, Y., RODİONOVA, Y., POLİVENOK, I., SHELEST, B. (2021). Soluble ST2 in Predicting Adverse Outcome after Revascularization with Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction. Düzce Tıp Fakültesi Dergisi, Cilt: 23 - Sayı: 2, 174–180. https://ajindex.com/articles/420080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Durante A, Camici PG. Novel insights into an "old" phenomenon: the no reflow. Int J Cardiol. 2015;187(1):273-80.
  2. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol. 2002;39(4):591-7.
  3. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145(1): 42-6.
  4. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012;58(1):257-66.
  5. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015;115(7 Suppl):3B-7B. Lepojärvi ES, Piira OP, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961-6. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259-67.
  6. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J. 2010;159(5):788-94.
  7. Jenkins WS, Roger VL, Jaffe AS, Weston SA, AbouEzzeddine OF, Jiang R, et al. Prognostic value of soluble ST2 after myocardial infarction: A community perspective. Am J Med. 2017;130(9):1112.e9-15. Maisel AS, Di Somma S. Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2). Eur Heart J. 2017;38(30):2325-33.
  8. Plawecki M, Morena M, Kuster N, Chenine L, Leray-Moragues H, Joveret B, et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: Impact on risk prediction. Mediators Inflamm. 2018;2018:3952526. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC S